

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application.

Claim 1 (Original): An implantable device for administration of a dopamine agonist to a mammal in need thereof, comprising a dopamine agonist and a biocompatible, nonerodible polymeric matrix,

wherein said dopamine agonist is encapsulated within said matrix, and wherein when said implantable device is implanted subcutaneously in said mammal, said dopamine agonist is continuously released *in vivo* over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a plasma level of at least about 0.01 ng/ml at steady state.

Claim 2 (Original): An implantable device according to claim 1, wherein the polymeric matrix comprises ethylene vinyl acetate copolymer (EVA).

Claim 3 (Original): An implantable device according to claim 2, wherein said EVA comprises about 33% vinyl acetate.

Claim 4 (Original): An implantable device according to claim 1, comprising about 10 to about 85% dopamine agonist.

Claim 5 (Currently Amended): An implantable device according to claim [[4]] 1, wherein said dopamine agonist is selected from the group consisting of apomorphine, lisuride, pergolide, bromocriptine, pramipexole, ropinerole, and rotigotine.

Claim 6 (Original): An implantable device according to claim 5, wherein said dopamine agonist is apomorphine.

Claim 7 (Original): An implantable device according to claim 1, wherein the sustained period of time is at least about 3 months.

Claim 8 (Original): An implantable device according to claim 1, wherein the implantable device is produced by an extrusion process.

Claim 9 (Original): An implantable device according to claim 8, comprising dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length.

Claim 10 (Original): An implantable device according to claim 9, wherein said implantable device releases about 0.1 to about 10 mg of dopamine agonist per day *in vitro* at steady state.

Claim 11 (Original): An implantable device according to claim 1, further comprising an anti-inflammatory agent encapsulated within said matrix.

Claim 12 (Original): An implantable device according to claim 11, wherein said anti-inflammatory agent is a steroid.

Claim 13 (Original): An implantable device according to claim 11, wherein said anti-inflammatory agent is a nonsteroidal anti-inflammatory drug ("NSAID").

Claim 14 (Original): An implantable device according to claim 11, wherein said anti-inflammatory agent is an antihistamine.

Claim 15 (Original): An implantable device according to claim 1, further comprising an antioxidant encapsulated within said matrix.

Claim 16 (Original): An implantable device for administration of a dopamine agonist to a mammal in need thereof, comprising a dopamine agonist and a biocompatible, nonerodible polymeric matrix,
wherein said dopamine agonist is encapsulated within said matrix, and
wherein when said implantable device is subcutaneously implanted in a mammal, said dopamine agonist is continuously released *in vivo* over a sustained period of time through pores that open to the surface of said matrix at a rate of at least about 0.1 mg of dopamine agonist per day at steady state.

Claim 17 (Original): An implantable device according to claim 16, wherein the polymeric matrix comprises EVA.

Claim 18 (Original): An implantable device according to claim 17, wherein said EVA comprises 33% vinyl acetate.

Claim 19 (Original): An implantable device according to claim 16, comprising about 10 to about 85% dopamine agonist.

Claim 20 (Original): An implantable device according to claim 16, wherein said dopamine agonist is selected from the group consisting of apomorphine, lisuride, pergolide, bromocriptine, pramipexole, ropinerole, and rotigotine.

Claim 21 (Original): An implantable device according to claim 20, wherein said dopamine agonist is apomorphine.

Claim 22 (Original): An implantable device according to claim 16, wherein the sustained period of time is at least about 3 months.

Claim 23 (Original): An implantable device according to claim 16, wherein the implantable device is produced by an extrusion process.

Claim 24 (Original): An implantable device according to claim 16, further comprising an anti-inflammatory agent encapsulated within said matrix.

Claim 25 (Original): An implantable device according to claim 24, wherein said anti-inflammatory agent is a steroid.

Claim 26 (Original): An implantable device according to claim 24, wherein said anti-inflammatory agent is a NSAID.

Claim 27 (Original): An implantable device according to claim 24, wherein said anti-inflammatory agent is an antihistamine.

Claim 28 (Currently Amended): An implantable device according to claim [[18]] 16, further comprising an antioxidant encapsulated within said matrix.

Claim 29 (Withdrawn): A method for administration of a dopamine agonist to a mammal in need thereof, the method comprising administering at least one implantable device subcutaneously,

wherein each of said at least one implantable devices comprises a dopamine agonist encapsulated within a biocompatible, nonerodible polymeric matrix,

wherein said dopamine agonist is continuously released *in vivo* from each of said at least one implantable devices over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a plasma level of at least about 0.01 ng/ml at steady state.

Claim 30 (Withdrawn): A method according to claim 29, wherein said at least one implantable device comprises a multiplicity of individual implantable devices, and wherein the

combination of said implantable devices continuously releases dopamine agonist *in vivo* over a sustained period of time at a rate that results in a plasma level of at least about 0.05 ng/ml at steady state.

Claim 31 (Withdrawn): A method according to claim 29, wherein the polymeric matrix comprises EVA.

Claim 32 (Withdrawn): A method according to claim 31, wherein said EVA comprises about 33% vinyl acetate.

Claim 33 (Withdrawn): A method according to claim 29, wherein each of said at least one implantable devices comprises at about 10 to about 85% dopamine agonist.

Claim 34 (Withdrawn): A method according to claim 33, wherein said dopamine agonist is selected from the group consisting of apomorphine, lisuride, pergolide, bromocriptine, pramipexole, ropinerole, and rotigotine.

Claim 35 (Withdrawn): A method according to claim 34, wherein said dopamine agonist is apomorphine.

Claim 36 (Withdrawn): A method according to claim 29, wherein said mammal has Parkinson's disease.

Claim 37 (Withdrawn): A method according to claim 29, wherein said mammal has toxin- or disease-induced parkinsonism.

Claim 38 (Withdrawn): A method according to claim 29, wherein said mammal has a condition selected from the group consisting of erectile dysfunction and restless leg syndrome.

Claim 39 (Withdrawn): A method according to claim 29, wherein the sustained period of time is at least about 3 months.

Claim 40 (Withdrawn): A method according to claim 29, wherein each of said at least one implantable devices is produced by an extrusion process.

Claim 41 (Withdrawn): A method according to claim 40, wherein each implantable device comprises dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length.

Claim 42 (Withdrawn): A method according to claim 41, wherein each implantable device releases at least about 0.1 mg of dopamine agonist per day *in vitro*.

Claim 43 (Withdrawn): A method according to claim 29, wherein each of said at least one implantable devices is subcutaneously implanted at a site selected from the group consisting of the upper arm, the back, and the abdomen.

Claim 44 (Withdrawn): A method according to claim 29, further comprising administration of an anti-inflammatory agent.

Claim 45 (Withdrawn): A method according to claim 44, wherein said anti-inflammatory agent is encapsulated in at least one of said at least one implantable devices.

Claim 46 (Withdrawn): A method according to claim 44, wherein said anti-inflammatory agent is encapsulated within a biocompatible, nonerodible polymeric matrix that does not comprise said dopamine agonist, and wherein said method comprises administration of said polymeric matrix comprising said anti-inflammatory agent subcutaneously.

Claim 47 (Withdrawn): A method according to claim 44, wherein said anti-inflammatory agent is administered via a route selected from the group consisting of local injection, systemic injection, subcutaneous injection, and oral administration.

Claim 48 (Withdrawn): A method according to claim 44, wherein said at least one implantable device further comprises an antioxidant.

Claim 49 (Original): A kit comprising at least one implantable device comprising a dopamine agonist encapsulated within a biocompatible, nonerodible polymeric matrix, wherein when said at least one implantable device is implanted subcutaneously in a mammal, said dopamine agonist is continuously released *in vivo* from each of said at least one implantable devices over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a plasma level of at least about 0.01 ng/ml at steady state and instructions for use in a method of administration of a dopamine agonist to a mammal in need thereof.

Claim 50 (Original): A kit according to claim 49, wherein said at least one implantable device comprises a multiplicity of individual implantable devices, and wherein when the combination of said implantable devices is implanted subcutaneously in a mammal, said implantable devices continuously release dopamine agonist *in vivo* over a sustained period of time at a rate that results in a plasma level of at least about 0.05 ng/ml at steady state.

Claim 51 (Original): A kit according to claim 49, wherein said implantable device releases dopamine agonist at a rate of at least about 0.1 mg per day *in vitro*.

Claim 52 (Currently Amended): A kit according to claim 49, wherein the polymeric matrix in each of said implantable devices comprises EVA.

Claim 53 (Original): A kit according to claim 52, wherein said EVA comprises about 33% vinyl acetate.

Claim 54 (Original): A kit according to claim 49, wherein each of said implantable devices comprises about 10 to about 85% dopamine agonist.

Claim 55 (Original): A kit according to claim 54, wherein said dopamine agonist is selected from the group consisting of apomorphine, lisuride, pergolide, bromocriptine, pramipexole, ropinerole, and rotigotine.

Claim 56 (Original): A kit according to claim 55, wherein said dopamine agonist is apomorphine.

Claim 57 (New): A kit according to claim 49, wherein the at least one implantable device further comprises an anti-inflammatory agent, and said anti-inflammatory agent is encapsulated in at least one of said at least one implantable device.

Claim 58 (New): A kit according to claim 49, wherein the at least one implantable device further comprising an anti-inflammatory agent, and said anti-inflammatory agent is encapsulated within a biocompatible, nonerodible polymeric matrix that does not comprise said dopamine agonist.

Claim 59 (New): An implantable device according to claim 5, wherein said dopamine agonist is lisuride.

Claim 60 (New): An implantable device according to claim 20, wherein said dopamine agonist is lisuride.

Claim 61 (New): A kit according to claim 55, wherein said dopamine agonist is lisuride.